Literature DB >> 17425755

Longer survival of liver transplant recipients with hepatitis virus coinfections.

Kinan Rifai1, Heiner Wedemeyer, Jens Rosenau, Jürgen Klempnauer, Christian P Strassburg, Michael P Manns, Hans L Tillmann.   

Abstract

Hepatitis virus coinfections [HBV plus HCV coinfection (HBV/HCV) or HBV plus HDV coinfection (HBV/HDV)] may progress more rapidly to cirrhosis than hepatitis B or C monoinfections in immunocompetent patients. Only limited information is available on the outcome of coinfected patients after liver transplantation. We studied survival rates of 204 patients with viral hepatitis transplanted at our center between 1972 and 1997. HBV/HDV and HBV/HCV coinfections were present in 23 and nine individuals, respectively, while 97 patients had monoinfection by HCV and 75 had HBV monoinfection. Survival of coinfected patients was significantly longer than that of monoinfected patients (14.4 +/- 0.9 vs. 8.5 +/- 0.6 yr; p = 0.0003). The same was true for graft survival (p = 0.0002). In Cox's regression, viral coinfection (p = 0.0001), absence of hepatocellular carcinoma (HCC) (p = 0.00001) and no retransplantation (p = 0.02) were independently associated with patient survival. After exclusion of patients with HCC (n = 62), survival of coinfected patients was still significantly longer than that of monoinfected individuals (p = 0.002). The improved outcome was similar for both HBV/HDV and HBV/HCV coinfections. In contrast to immunocompetent patients, individuals with multiple hepatitis virus infections had an improved outcome after liver transplantation. Thus, viral coinfections may be associated with ameliorated courses of diseases under certain conditions.

Entities:  

Mesh:

Year:  2007        PMID: 17425755     DOI: 10.1111/j.1399-0012.2006.00636.x

Source DB:  PubMed          Journal:  Clin Transplant        ISSN: 0902-0063            Impact factor:   2.863


  6 in total

1.  Liver transplantation for hepatitis B virus: Decreasing indication and changing trends.

Authors:  Waleed Al-Hamoudi; Hussien Elsiesy; Abdulrahman Bendahmash; Nasser Al-Masri; Safiyya Ali; Naglaa Allam; Mohammed Al Sofayan; Hamad Al Bahili; Mohammed Al Sebayel; Dieter Broering; Sammy Saab; Faisal Abaalkhail
Journal:  World J Gastroenterol       Date:  2015-07-14       Impact factor: 5.742

Review 2.  Recent breakthroughs in the treatment of chronic hepatitis Delta.

Authors:  Giuseppina Brancaccio; Laura Gaeta; Alessandro Vitale; Giovanni B Gaeta
Journal:  Infez Med       Date:  2022-06-01

Review 3.  Significance of hepatitis virus infection in the oncogenic initiation of hepatocellular carcinoma.

Authors:  Caecilia H C Sukowati; Korri E El-Khobar; Susan I Ie; Beatrice Anfuso; David H Muljono; Claudio Tiribelli
Journal:  World J Gastroenterol       Date:  2016-01-28       Impact factor: 5.742

4.  Viral status at the time of liver transplantation for hepatocellular carcinoma: a modern predictor of longterm survival.

Authors:  Ryan T Groeschl; Johnny C Hong; Kathleen K Christians; Kiran K Turaga; Susan Tsai; Charles H C Pilgrim; T Clark Gamblin
Journal:  HPB (Oxford)       Date:  2013-06-19       Impact factor: 3.647

Review 5.  Hepatitis D virus and liver transplantation: Indications and outcomes.

Authors:  Haris Muhammad; Aniqa Tehreem; Muhammad Baraa Hammami; Peng-Sheng Ting; Ramzan Idilman; Ahmet Gurakar
Journal:  World J Hepatol       Date:  2021-03-27

Review 6.  Hepatitis B virus/hepatitis D virus epidemiology: Changes over time and possible future influence of the SARS-CoV-2 pandemic.

Authors:  Caterina Sagnelli; Mariantonietta Pisaturo; Caterina Curatolo; Alessio Vinicio Codella; Nicola Coppola; Evangelista Sagnelli
Journal:  World J Gastroenterol       Date:  2021-11-14       Impact factor: 5.742

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.